These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 15533590)

  • 1. Prognostic significance and different properties of survivin splicing variants in gastric cancer.
    Meng H; Lu C; Mabuchi H; Tanigawa N
    Cancer Lett; 2004 Dec; 216(2):147-55. PubMed ID: 15533590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between transcriptional expression of survivin isoforms and clinicopathological findings in human colorectal carcinomas.
    Suga K; Yamamoto T; Yamada Y; Miyatake S; Nakagawa T; Tanigawa N
    Oncol Rep; 2005 May; 13(5):891-7. PubMed ID: 15809755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties.
    Mahotka C; Wenzel M; Springer E; Gabbert HE; Gerharz CD
    Cancer Res; 1999 Dec; 59(24):6097-102. PubMed ID: 10626797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression of survivin splice isoforms in medulloblastomas.
    Li XN; Shu Q; Su JM; Adesina AM; Wong KK; Perlaky L; Antalffy BA; Blaney SM; Lau CC
    Neuropathol Appl Neurobiol; 2007 Feb; 33(1):67-76. PubMed ID: 17239009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression of survivin in bone marrow cells from patients with acute lymphocytic leukemia and chronic lymphocytic leukemia.
    Nakagawa Y; Yamaguchi S; Hasegawa M; Nemoto T; Inoue M; Suzuki K; Hirokawa K; Kitagawa M
    Leuk Res; 2004 May; 28(5):487-94. PubMed ID: 15068902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression.
    Krieg A; Mahotka C; Krieg T; Grabsch H; Müller W; Takeno S; Suschek CV; Heydthausen M; Gabbert HE; Gerharz CD
    Br J Cancer; 2002 Mar; 86(5):737-43. PubMed ID: 11875736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker.
    Nouraee N; Mowla SJ; Ozhand A; Parvin M; Ziaee SA; Hatefi N
    Urol J; 2009; 6(2):101-8. PubMed ID: 19472128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential expression of survivin and its splice variants, survivin-DeltaEx3 and survivin-2B, in bladder cancer.
    Atlasi Y; Mowla SJ; Ziaee SA
    Cancer Detect Prev; 2009; 32(4):308-13. PubMed ID: 19186007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of survivin on cell proliferation and apoptosis in gastric cancer.
    Wakana Y; Kasuya K; Katayanagi S; Tsuchida A; Aoki T; Koyanagi Y; Ishii H; Ebihara Y
    Oncol Rep; 2002; 9(6):1213-8. PubMed ID: 12375022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct expression of Survivin splice variants in breast carcinomas.
    Vegran F; Boidot R; Oudin C; Riedinger JM; Lizard-Nacol S
    Int J Oncol; 2005 Oct; 27(4):1151-7. PubMed ID: 16142334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression level of wild-type survivin in gastric cancer is an independent predictor of survival.
    Meng H; Lu CD; Sun YL; Dai DJ; Lee SW; Tanigawa N
    World J Gastroenterol; 2004 Nov; 10(22):3245-50. PubMed ID: 15484293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of survivin splice variants in pediatric acute precursor B lymphoblastic leukemia.
    Tröger A; Siepermann M; Mahotka C; Wethkamp N; Bülle H; Laws HJ; Escherich G; Janka-Schaub G; Göbel U; Dilloo D
    Klin Padiatr; 2007; 219(3):127-33. PubMed ID: 17525905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo expression patterns of survivin and its splicing variants in chronic liver disease and hepatocellular carcinoma.
    Takashima H; Nakajima T; Moriguchi M; Sekoguchi S; Nishikawa T; Watanabe T; Katagishi T; Kimura H; Minami M; Itoh Y; Kagawa K; Okanoue T
    Liver Int; 2005 Feb; 25(1):77-84. PubMed ID: 15698402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of apoptosis proteins in human cervical cancer.
    Espinosa M; Cantú D; Herrera N; Lopez CM; De la Garza JG; Maldonado V; Melendez-Zajgla J
    BMC Cancer; 2006 Feb; 6():45. PubMed ID: 16504151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential subcellular localization of functionally divergent survivin splice variants.
    Mahotka C; Liebmann J; Wenzel M; Suschek CV; Schmitt M; Gabbert HE; Gerharz CD
    Cell Death Differ; 2002 Dec; 9(12):1334-42. PubMed ID: 12478470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer.
    Warnecke-Eberz U; Hokita S; Xi H; Higashi H; Baldus SE; Metzger R; Brabender J; Bollschweiler E; Mueller RP; Dienes HP; Hoelscher AH; Schneider PM
    Oncol Rep; 2005 Jun; 13(6):1241-6. PubMed ID: 15870949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma.
    Ikeguchi M; Kaibara N
    Br J Cancer; 2002 Oct; 87(8):883-7. PubMed ID: 12373603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Up-regulation of survivin mRNA might be a marker for non-invasive detection of non-small cell lung cancer rather than for prognosis.
    Warnecke-Eberz U; Baldus SE; Bollschweiler E; Hoelscher AH; Metzger R
    Anticancer Res; 2008; 28(3A):1525-9. PubMed ID: 18630507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated expression of survivin-splice variants predicts a poor outcome for soft-tissue sarcomas patients.
    Taubert H; Kappler M; Bache M; Bartel F; Köhler T; Lautenschläger C; Blümke K; Würl P; Schmidt H; Meye A; Hauptmann S
    Oncogene; 2005 Aug; 24(33):5258-61. PubMed ID: 15856009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of survivin mRNA associates with apoptosis, proliferation and histologically aggressive features in hepatocellular carcinoma.
    Morinaga S; Nakamura Y; Ishiwa N; Yoshikawa T; Noguchi Y; Yamamoto Y; Rino Y; Imada T; Takanashi Y; Akaike M; Sugimasa Y; Takemiya S
    Oncol Rep; 2004 Dec; 12(6):1189-94. PubMed ID: 15547736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.